CL2011000913A1 - Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion. - Google Patents

Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion.

Info

Publication number
CL2011000913A1
CL2011000913A1 CL2011000913A CL2011000913A CL2011000913A1 CL 2011000913 A1 CL2011000913 A1 CL 2011000913A1 CL 2011000913 A CL2011000913 A CL 2011000913A CL 2011000913 A CL2011000913 A CL 2011000913A CL 2011000913 A1 CL2011000913 A1 CL 2011000913A1
Authority
CL
Chile
Prior art keywords
antigens
tetanus
diphtheria
hepatitis
optionally
Prior art date
Application number
CL2011000913A
Other languages
English (en)
Inventor
Rajesh Jain
Sukhjeet Sing
Lavit Jambu
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CL2011000913A1 publication Critical patent/CL2011000913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Vacuna combinada estable y completamente liquida que comprende antígenos diftérico, tetánico, pertusico de células completas, y virus de poliomielitis y opcionalmente uno o mas antígenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricación.
CL2011000913A 2008-10-24 2011-04-21 Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion. CL2011000913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2437DE2008 2008-10-24

Publications (1)

Publication Number Publication Date
CL2011000913A1 true CL2011000913A1 (es) 2012-01-20

Family

ID=42119002

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000913A CL2011000913A1 (es) 2008-10-24 2011-04-21 Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion.

Country Status (14)

Country Link
US (1) US20110195087A1 (es)
EP (2) EP2361094A4 (es)
JP (1) JP2012506420A (es)
CN (1) CN102196817B (es)
AP (1) AP2011005700A0 (es)
AR (1) AR073957A1 (es)
BR (1) BRPI0920629A2 (es)
CA (1) CA2741393A1 (es)
CL (1) CL2011000913A1 (es)
CO (1) CO6430435A2 (es)
MA (1) MA32821B1 (es)
PE (1) PE20100365A1 (es)
RU (2) RU2504398C2 (es)
WO (1) WO2010046934A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633898B (zh) * 2012-04-23 2013-11-27 成都欧林生物科技股份有限公司 一种Hib多糖与蛋白结合工艺的优化方法
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
MA42317B2 (fr) * 2015-09-16 2021-11-30 Lg Chemical Ltd Composition de vaccin combinée pour administration multiple
AU2017316768B2 (en) * 2016-08-26 2024-04-11 Serum Institute Of India Private Limited Multivalent vaccine composition
BR112020000999A2 (pt) * 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação
CA3115803A1 (en) * 2018-10-12 2020-04-16 Serum Institute Of India Private Ltd. Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097140A (en) 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
US3097142A (en) 1960-03-30 1963-07-09 Merck & Co Inc Benzyl alcohol stabilized polio vaccines and production thereof
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2259415A1 (en) 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
DK1296715T4 (en) * 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
GB0223355D0 (en) 2002-10-08 2002-11-13 Chiron Spa Vaccine
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
KR20030069918A (ko) 2003-06-25 2003-08-27 주식회사 삼정산업 간편 조립식 파렛트 판재, 간편 조립식 파렛트 중간지지구및 간편 조립식 파렛트와 그의 제작방법
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
EP1793852A1 (en) * 2004-08-27 2007-06-13 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина

Also Published As

Publication number Publication date
PE20100365A1 (es) 2010-05-21
US20110195087A1 (en) 2011-08-11
AP2011005700A0 (en) 2011-06-30
MA32821B1 (fr) 2011-11-01
EP2361094A4 (en) 2012-12-05
RU2011120309A (ru) 2012-11-27
EP2361094A1 (en) 2011-08-31
BRPI0920629A2 (pt) 2016-01-12
RU2011135761A (ru) 2013-03-10
RU2613295C2 (ru) 2017-03-15
AR073957A1 (es) 2010-12-15
RU2504398C2 (ru) 2014-01-20
CA2741393A1 (en) 2010-04-29
EP2529750A1 (en) 2012-12-05
CN102196817A (zh) 2011-09-21
WO2010046934A1 (en) 2010-04-29
CO6430435A2 (es) 2012-04-30
JP2012506420A (ja) 2012-03-15
CN102196817B (zh) 2016-04-06

Similar Documents

Publication Publication Date Title
CL2011000914A1 (es) Vacuna combinada estable completamente liquida que comprende antigenos difterico, tetanico, pertusico acelular, de haemophilus influenzae, y de virus de poliomielitis en donde el antigeno se haemophilus influenzae no esta sustancialmente absorbido sobre ningun adyuvante; y proceso de fabricacion.
CY1111180T1 (el) Ελαττωση δυνητικων ιατρογενων κινδυνων συναφων με τα εμβολια γριπης
MX2009006469A (es) Metodo de duplicacion del virus de la influenza en cultivo.
BRPI0807160A2 (pt) vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
PT2752484T (pt) Método para preparar um meio de cultura básico para células estaminais mesenquimais, meio de cultura básico para células estaminais mesenquimais, e agente terapêutico celular cultivado e diferenciado usando o mesmo
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
NO20081127L (no) Vaksinering mot Dengue virusinfeksjon
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
DK1863941T3 (da) Infektiøst, kimæriskt hepatitis-c-virus, fremgangsmåder til fremstilling deraf og fremgangsmåder til anvendelse deraf
ATE516817T1 (de) Impfstoffe zur immunisierung gegen helicobacter
AR073957A1 (es) Vacuna de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
WO2010000127A9 (en) Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
EP2075005A4 (en) IPV-DPT VACCINE
UA100849C2 (ru) Способ репликации вируса гриппа в культуре
DE602004023238D1 (de) Methoden zur Kultivierung von Antigen presentierenden Immunzellen
PL1945252T3 (pl) Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
WO2010006326A3 (en) Methods and compositions for spore-based vaccines
WO2010110931A3 (en) Glycoconjugate vaccines
DK2084266T3 (da) Cellekultursystem, fremgangsmåde til fremstillingen deraf og anvendelse i prækliniske undersøgelser
Akande et al. Academic excellence in architectural education and opportunities and challenges for the architect graduate
MX2010004706A (es) Variantes ingenierizadas de pertactina para uso vacunal.
HK1159656A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant